UroGen Pharma Ltd. (URGN) stock
URGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
$29.79−0.08 (-0.27%)
Close on Nov 18, 2026Market cap $1.46BP/E –Yield –
UroGen Pharma operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
UroGen Pharma's operating cash flow for the twelve months ending Jun 30, 2026 was -$158.92M. For fiscal 2025 it was -$162.44M. The highest annual figure on record is $4.19M in fiscal 2016.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$162.44M | – |
| FY2024 | Dec 31, 2024 | -$96.77M | – |
| FY2023 | Dec 31, 2023 | -$76.38M | – |
| FY2022 | Dec 31, 2022 | -$87.56M | – |
| FY2021 | Dec 31, 2021 | -$84.89M | – |
| FY2020 | Dec 31, 2020 | -$105.89M | – |
| FY2019 | Dec 31, 2019 | -$71.02M | – |
| FY2018 | Dec 31, 2018 | -$37.33M | – |
| FY2017 | Dec 31, 2017 | -$9.57M | -328.4% |
| FY2016 | Dec 31, 2016 | $4.19M | – |
| FY2015 | Dec 31, 2015 | -$7.18M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$33.01M | – |
| Q1 FY2026 | Mar 31, 2026 | -$45.32M | – |
| Q4 FY2025 | Dec 31, 2025 | -$38.33M | – |
| Q3 FY2025 | Sep 30, 2025 | -$42.27M | – |
| Q2 FY2025 | Jun 30, 2025 | -$39.83M | – |
| Q1 FY2025 | Mar 31, 2025 | -$42.02M | – |
| Q4 FY2024 | Dec 31, 2024 | -$13.62M | – |
| Q3 FY2024 | Sep 30, 2024 | -$27.66M | – |
| Q2 FY2024 | Jun 30, 2024 | -$23.75M | – |
| Q1 FY2024 | Mar 31, 2024 | -$31.74M | – |
| Q4 FY2023 | Dec 31, 2023 | -$13.00M | – |
| Q3 FY2023 | Sep 30, 2023 | -$17.30M | – |
| Q2 FY2023 | Jun 30, 2023 | -$20.27M | – |
| Q1 FY2023 | Mar 31, 2023 | -$25.81M | – |
| Q4 FY2022 | Dec 31, 2022 | -$21.75M | – |
| Q3 FY2022 | Sep 30, 2022 | -$17.61M | – |
| Q2 FY2022 | Jun 30, 2022 | -$24.20M | – |
| Q1 FY2022 | Mar 31, 2022 | -$24.00M | – |
| Q4 FY2021 | Dec 31, 2021 | -$20.07M | – |
| Q3 FY2021 | Sep 30, 2021 | -$18.48M | – |
| Q2 FY2021 | Jun 30, 2021 | -$18.95M | – |
| Q1 FY2021 | Mar 31, 2021 | -$27.40M | – |
| Q4 FY2020 | Dec 31, 2020 | -$21.24M | – |
| Q3 FY2020 | Sep 30, 2020 | -$25.08M | – |
| Q2 FY2020 | Jun 30, 2020 | -$23.93M | – |
| Q1 FY2020 | Mar 31, 2020 | -$35.64M | – |
| Q4 FY2019 | Dec 31, 2019 | -$26.00M | – |
| Q3 FY2019 | Sep 30, 2019 | -$12.53M | – |
| Q2 FY2019 | Jun 30, 2019 | -$14.56M | – |
| Q1 FY2019 | Mar 31, 2019 | -$17.93M | – |
| Q4 FY2018 | Dec 31, 2018 | -$10.28M | – |
| Q3 FY2018 | Sep 30, 2018 | -$9.28M | -457.3% |
| Q2 FY2018 | Jun 30, 2018 | -$8.15M | – |
| Q1 FY2018 | Mar 31, 2018 | -$9.62M | – |
| Q4 FY2017 | Dec 31, 2017 | -$5.96M | – |
| Q3 FY2017 | Sep 30, 2017 | $2.60M | – |
| Q2 FY2017 | Jun 30, 2017 | -$3.46M | – |
| Q1 FY2017 | Mar 31, 2017 | -$2.75M | – |
See a number that looks wrong?